Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Retained Earnings (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Retained Earnings for 6 consecutive years, with -$504.9 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 990025.49% to -$504.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$504.9 million through Dec 2025, down 990025.49% year-over-year, with the annual reading at -$504.9 million for FY2025, 990025.49% down from the prior year.
  • Retained Earnings for Q4 2025 was -$504.9 million at TScan Therapeutics, down from -$481.9 million in the prior quarter.
  • The five-year high for Retained Earnings was $51000.0 in Q4 2024, with the low at -$504.9 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$231.2 million, with a median of -$205.0 million recorded in 2023.
  • The sharpest move saw Retained Earnings soared 100.02% in 2024, then plummeted 990025.49% in 2025.
  • Over 5 years, Retained Earnings stood at -$92.2 million in 2021, then crashed by 71.86% to -$158.4 million in 2022, then tumbled by 56.33% to -$247.6 million in 2023, then surged by 100.02% to $51000.0 in 2024, then tumbled by 990025.49% to -$504.9 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$504.9 million, -$481.9 million, and -$446.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.